48 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp04376 | MAC1 | GFGMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 10 ± 4 µM |
| dbacp04377 | MAC1 | GFGMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 23 ± 4 µM |
| dbacp04378 | MAC1 | GFGMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 12 ± 6 µM |
| dbacp04379 | MAC1/1 | gfgmalkllkkvl | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 12 ± 4 µM |
| dbacp04380 | MAC1/1 | gfgmalkllkkvl | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 19 ± 2 µM |
| dbacp04381 | MAC1/1 | gfgmalkllkkvl | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 11 µM |
| dbacp04382 | MAC1/10 | GFKMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 15 ± 6 µM |
| dbacp04383 | MAC1/10 | GFKMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp04384 | MAC1/10 | GFKMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 16 µM |
| dbacp04385 | MAC1/16 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 32 ± 2 µM |
| dbacp04386 | MAC1/16 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 100 µM |
| dbacp04387 | MAC1/16 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 70 µM |
| dbacp04388 | MAC1/19 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 21 ± 4 µM |
| dbacp04389 | MAC1/19 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 68 ± 2 µM |
| dbacp04390 | MAC1/19 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 43 ± 11 µM |
| dbacp04391 | MAC1/2 | AFGMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 16 ± 3 µM |
| dbacp04392 | MAC1/2 | AFGMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 16 µM |
| dbacp04393 | MAC1/2 | AFGMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 17 µM |
| dbacp04394 | MAC1/20 | GFGMALOLLOOVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 10 ± 1 µM |
| dbacp04395 | MAC1/20 | GFGMALOLLOOVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 35 ± 4 µM |
| dbacp04396 | MAC1/20 | GFGMALOLLOOVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 25 ± 3 µM |
| dbacp04397 | MAC1/21 | GFGMALRLLRRVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 9 ± 3 µM |
| dbacp04398 | MAC1/21 | GFGMALRLLRRVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 17 ± 2 µM |
| dbacp04399 | MAC1/21 | GFGMALRLLRRVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 22 ± 4 µM |
| dbacp04400 | MAC1/24 | GFGMALKL-(AC6C)-KKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 8 ± 2 µM |
| dbacp04401 | MAC1/24 | GFGMALKL-(AC6C)-KKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 16 ± 1 µM |
| dbacp04402 | MAC1/24 | GFGMALKL-(AC6C)-KKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 11 µM |
| dbacp04403 | MAC1/25 | GFGMALK-(AC6C)-LKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 7 ± 1 µM |
| dbacp04404 | MAC1/25 | GFGMALK-(AC6C)-LKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 14 ± 1 µM |
| dbacp04405 | MAC1/25 | GFGMALK-(AC6C)-LKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 12 ± 2 µM |
| dbacp04406 | MAC1/26 | GFGMA-(AC6C)-KLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 8 ± 2 µM |
| dbacp04407 | MAC1/26 | GFGMA-(AC6C)-KLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 18 ± 1 µM |
| dbacp04408 | MAC1/26 | GFGMA-(AC6C)-KLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 9 ± 2 µM |
| dbacp04409 | MAC1/3 | LFGMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 9 ± 2 µM |
| dbacp04410 | MAC1/3 | LFGMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 11 ± 1 µM |
| dbacp04411 | MAC1/3 | LFGMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 22 µM |
| dbacp04412 | MAC1/4 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 15 ± 5 µM |
| dbacp04413 | MAC1/4 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 49 ± 9 µM |
| dbacp04414 | MAC1/4 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 29 µM |
| dbacp04415 | MAC1/6 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 8 ± 2 µM |
| dbacp04416 | MAC1/6 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 29 ± 3 µM |
| dbacp04417 | MAC1/6 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 15 µM |
| dbacp04418 | MAC1/9 | GFKMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 8 ± 1 µM |
| dbacp04419 | MAC1/9 | GFKMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 13 ± 3 µM |
| dbacp04420 | MAC1/9 | GFKMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 14 ± 4 µM |
| dbacp04421 | MAC2 | GTGLPMSERRKIMLMMR | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : > 100 µM |
| dbacp04422 | MAC2 | GTGLPMSERRKIMLMMR | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 100 µM |
| dbacp04423 | MAC2 | GTGLPMSERRKIMLMMR | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 32 µM |